Former spy chief’s trial raises heat on Pakistan’s Imran Khan
Army could try ex-prime minister for treason in military court, say analysts
Imran Khan
By Eastern Eye Sep 12, 2024
PAKISTAN’S unprecedented arrest and court-martial of a former spy chief could be the precursor to prosecuting the jailed ex-prime minister Imran Khan on charges of treason and attempting to incite a mutiny in the military, according to government officials and analysts.
Khan is on trial in a civilian court for allegedly abetting the violence, a charge he has denied. But he can face more serious charges of treason and mutiny after last month’s arrest of Lieutenant General Faiz Hameed, a Khan ally and former chief of the powerful Inter-Services Intelligence (ISI) agency, officials and analysts said.
Treason and mutiny are tried by military court. Such trials are not open to the public, and the charges carry a maximum punishment of death.
“I think the arrest will be used to put pressure on Faiz Hameed to provide information that helps implicate Khan in the May 9 violence which the army chief sees as mutiny and an act of treason,” said author and defence analyst Ayesha Siddiqa, who called Hameed’s arrest a “political bombshell”.
Government officials have repeatedly said Hameed worked with Khan to plan the riots. Defence minister Khawaja Asif told Geo TV last month that Khan provided the manpower while Hameed “masterminded the conspiracy”.
The military did not respond to a Reuters request for comment.
The current army chief, General Asim Munir, said in May there could be “no compromise or deal with the planners and architects of this dark chapter in our history”. He did not name anybody.
Hameed could not be reached for comment and it was not immediately known who his lawyer was.
Asked whether Khan could be tried in a military court, spokesman Major General Ahmed Sharif Chaudhry told a news conference last Thursday (5) the question was “hypothetical”.
But he added: “Anyone who uses any person or persons who are bound by the Army Act for his personal or political interests, and there is evidence available about that, the law will take its own course.”
Khan has said Hameed’s arrest was meant to ultimately target him as other cases against him were falling part.
“It is a drama to try my case in a military court,” he was quoted as saying by his lawyer Naeem Panjutha during a recent hearing in jail.
Hameed is being tried by court-martial on charges of corruption, misuse of power in service and violation of the Army Act after his 2022 retirement, the military says. The charges are punishable by a jail sentence of up to 14 years.
Imran Khan
The court-martial has begun, said Chaudhry, the military spokesman.
“The retired officer is also accused of transgressing legal and constitutional boundaries for his personal interest at the behest of some particular political elements,” he said.
Khan handpicked Hameed in 2019 as ISI chief, one of the most powerful positions in Pakistan, at the intersection of domestic politics, the military and Pakistan’s foreign relations.
Hameed’s transfer from the ISI to a corps command two years later, which Khan initially opposed, highlighted the first public signs of divisions between Khan and Bajwa, the then army chief.
The former leader has acknowledged in interviews to local media that he wanted Hameed to remain as the head of the ISI in 2021, when he said the opposition was planning to oust him.
Hameed’s arrest came after a string of legal victories for Khan in civilian courts, despite allegations by several senior judges – in a letter to the chief justice that was published in local media – of pressure to decide cases against the former prime minister. While the military denies pressuring judges, the charges have put the two institutions at loggerheads, analysts said.
It would be in the interest of the army’s top brass to hold a trial under military law, since it would “forestall any judicial intervention” in support of Khan, said Husain Haqqani, a former Pakistan ambassador to the US and a senior fellow at the Hudson Institute.
“By their very nature, military courts are secretive and their procedures arcane,” said Shuja Nawaz, a fellow at the Atlantic Council’s South Asia Center in Washington in the US.
Media are not allowed at military trials, and verdicts are announced in short statements from the military without details of evidence.
Siddiqa, Haqqani and other analysts said they believed the army, by trying one of its own, was demonstrating it was not ready to provide any space to Khan, who won the most seats in a national election earlier this year despite being in jail.
“Khan’s trial by a military court would signal the army leadership’s resolve to eliminate him from the political scene no matter how high the cost,” said Yousuf Nazar, a political analyst and author of Pakistan: The Gathering Storm.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.